← Leaderboards
Alfred S Lewin
University Of Florida
$10,095,035
Attributed
$10,095,035
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $972.4K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$10,095,035 · 5
By mechanism
R01$10,095,035 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- John R Guy$21,490,889
- Sara Marie Raser Palmer$1,053,403
- Janani Sampath$660,136
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyRetinaPhotoreceptorsBlindnessLeadMouse ModelCellsProteinsGenesRetinitis PigmentosaDependovirusDesignAdeno-Associated Viral VectorElderlyChoroidal NeovascularizationAge Related Macular DegenerationMaculaRetinal DiseasesCatalytic RnaAffectMutationPathologyEnzymesMitochondria
Grant awards (26)
Testing Gene Therapy in Models of Geographic Atrophy$523,020
R01 · FY2020 · EY · contact PI
Testing Gene Therapy in Models of Geographic Atrophy$523,020
R01 · FY2019 · EY · contact PI
Testing Gene Therapy in Models of Geographic Atrophy$523,020
R01 · FY2018 · EY · contact PI
Testing Gene Therapy in Models of Geographic Atrophy$523,020
R01 · FY2017 · EY · contact PI
Testing Gene Therapy in Models of Geographic Atrophy$535,520
R01 · FY2016 · EY · contact PI
Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for A$502,268
R01 · FY2013 · EY · contact PI
Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for A$542,357
R01 · FY2012 · EY · contact PI
Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for A$497,955
R01 · FY2011 · EY · contact PI
Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for A$40,024
R01 · FY2011 · EY · contact PI
RDS mutations: Gene therapy for ADRP, macular degeneration and pattern dystrophy$571,186
R01 · FY2010 · EY · contact PI
RDS mutations: Gene therapy for ADRP, macular degeneration and pattern dystrophy$567,494
R01 · FY2009 · EY · contact PI
Targeting mitochondrial gene expression in the retina$351,004
R01 · FY2009 · EY · contact PI
RDS mutations: Gene therapy for ADRP, macular degeneration and pattern dystrophy$53,916
R01 · FY2009 · EY · contact PI
RDS mutations: Gene therapy for ADRP, macular degeneration and pattern dystrophy$466,752
R01 · FY2008 · EY · contact PI
Targeting mitochondrial gene expression in the retina$343,984
R01 · FY2008 · EY · contact PI
RDS mutations: Gene therapy for ADRP, macular degeneration and pattern dystrophy$488,628
R01 · FY2007 · EY · contact PI
Targeting mitochondrial gene expression in the retina$351,004
R01 · FY2007 · EY · contact PI
Targeting mitochondrial gene expression in the retina$392,320
R01 · FY2006 · EY · contact PI
Targeting mitochondrial gene expression in the retina$359,200
R01 · FY2005 · EY
AUTOSOMAL DOMINANT EYE DISEASE: CATALYTIC RNA TREATMENT$325,383
R01 · FY2005 · EY
Targeting mitochondrial gene expression in the retina$40,705
R01 · FY2005 · EY
AUTOSOMAL DOMINANT EYE DISEASE: CATALYTIC RNA TREATMENT$325,564
R01 · FY2004 · EY
AUTOSOMAL DOMINANT EYE DISEASE: CATALYTIC RNA TREATMENT$324,621
R01 · FY2003 · EY
AUTOSOMAL DOMINANT EYE DISEASE: CATALYTIC RNA TREATMENT$324,770
R01 · FY2002 · EY
AUTOSOMAL DOMINANT EYE DISEASE: CATALYTIC RNA TREATMENT$320,404
R01 · FY2001 · EY
TX OF AUTOSOMAL DOMINANT EYE DISEASE USING CATALYTIC RNA$277,896
R01 · FY2000 · EY